Роль В-лимфоцитов и плазматических клеток в патогенезе воспалительных заболеваний кишечника

Цель: Изучить литературу относительно роли В-лимфоцитов и плазматических клеток в патогенезе болезни Крона (БК) и язвенного Колита (ЯК). Материалы и методы: Проанализировано 86 литературных источников из баз данных Scopus, Web of Science, Google scholar, PubMed, а также находящихся в свободном доступе в Google. Результаты. БК и ЯК являются серьезной проблемой здравоохранения в связи с широкой распространенностью, объективными трудностями лечения, обусловленных сложностью патогенеза и продолжающимся поиском эффективных лекарственных препаратов. На сегодняшний день наиболее успешными методами патогенетической терапии считается терапия антицитокинами и использование лекарственных средств, направленных на подавление Т-клеточного ответа. Заключение. Показано, что при использовании существующих методов лечения у части пациентов они не эффективны. Изучение В-лимфоцитов и плазматических клеток собственной пластинки слизистой оболочки кишки как возможной терапевтической мишени при лечении ЯК и БК является актуальным.

воспалительные заболевания кишечника, В-лимфоциты, плазматические клетки

1. Chou J-W., Lai H-C., Chang C-H. et al. Epidemiology and Clinical Outcomes of Inflammatory Bowel Disease: A Hospital-Based Study in Central Taiwan. Gastroenterol Res Pract. 2019 Jun 13;2019:4175923. doi: 10.1155/2019/4175923.

2. Pasvol T.J., Horsfall L., Bloom S., Segal A. W., Sabin C., Field N., Rait G. Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open. 2020 Jul 19;10(7): e036584. doi: 10.1136/bmjopen-2019-036584.

3. Osikov M. V., Simonyan E. V., Listik E. V., Bakeeva A. E., Bivalkevich V. A. Inflammatory bowel disease: choosing of the optimal experimental model. Modern problems of science and education. 2017; (3) Available at: https://science-education.ru/ru/article/view?id=26524&ysclid=lb4wqditj1291559416 Access 05.01.2023.@@ Осиков М. В., Симонян Е. В., Листик Е. В., Бакеева А. Е., Бивалькевич В. А. Воспалительные заболевания кишечника: выбор оптимальной экспериментальной модели. Современные проблемы науки и образования. - 2017; - № 3: https://science-education.ru/ru/article/view?id=26524&ysclid=lb4wqditj1291559416

4. Gorelov A. V., Kanner E. V. Inflammatory bowel diseases in children: peculiarities of the disease course and therapy. Meditsinskiy sovet = Medical Council. 2018;(2):140-145. (In Russ.) doi: 10.21518/2079-701X-2018-2-140-145.@@ Горелов А. В., Каннер Е. В. Воспалительные заболевания кишечника у детей: особенности течения и терапии. Медицинский совет. 2018; 2: 140-145.

5. Glavnov P. V., Lebedeva N. N., Kashchenko V. A., Varzin S. A. Ulcer colitis and crohn’s disease. current state of a problem of an etiology, early diagnostics and treatment (review of literature). Vestniks of Saint Petersburg University. 2015; 11(4): 48-72. (in Russ.)@@ Главнов П. В., Лебедева Н. Н., Кащенко В. А., Варзин С. А. Язвенный колит и болезнь Крона. Современное состояние проблемы этиологии, ранней диагностики и лечения (обзор литературы). Вестник СПбГУ. 2015; 11(4): 48-72.

6. Porter R.J., Kalla R., Ho G. T. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res. 2020 Apr 24;9: F1000 Faculty Rev-294. doi: 10.12688/f1000research.20805.1.

7. Vakhitov T. Ya., Kudryavtsev I. V., Sall T. S., Lazareva N. M., Kononova S. V., Khavkin A. I., Sitkin S. I. T-helper cell subsets, key cytokines and chemokines in the pathogenesis of inflammatory bowel disease (Part 2). Vopr. prakt. pediatr. (Clinical Practice in Pediatrics). 2021; 16(1): 41-51. (In Russ.) doi: 10.20953/1817-7646-2021-1-41-51.@@ Вахитов Т. Я., Кудрявцев И. В., Салль Т. С. и др. Субпопуляции Т-хелперов, ключевые цитокины и хемокины в патогенезе воспалительных заболеваний кишечника (часть 2). Вопросы практической педиатрии. 2021; 16(1): 41-51.

8. Jodeleit H., Winkelmann P., Caesar J. et al. Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells. Dis Model Mech. 2021 Jan 1;14(1): dmm046995. doi: 10.1242/dmm.046995.

9. Tyler C. J., Guzman M., Lundborg L. R. et al. Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis. Mucosal Immunol. 2022 Jan;15(1):109-119. doi: 10.1038/s41385-021-00445-z.

10. Chaudhary C. L., Gurung P., Jang S. et al. Synthesis, activity and mechanism of alkoxy-, carbamato-, sulfonamido-, thioureido-, and ureido-derivatives of 2,4,5-trimethylpyridin-3-ol against inflammatory bowel disease. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1-20. doi: 10.1080/14756366.2019.

11. Register of medicines of Russia RLS Encyclopedia of medicines. (in Russ.) Available at: https://www.rlsnet.ru/active-substance/vedolizumab-3616?ysclid=lb511b80y7934578827 Access: 01.05.2023.@@ Регистр лекарственных средств России РЛС Энциклопедия лекарств: https://www.rlsnet.ru/active-substance/vedolizumab-3616?ysclid=lb511b80y7934578827

12. Ailamazyan A. N. The role of signaling molecules in pathogenesis of gastrointestinal tract diseases: optimization of diagnostics and target therapy. Molecular medicine. 2013;(5): 3-7. (in Russ.)@@ Айламазян А. Н. Роль сигнальных молекул в патогенезе заболеваний желудочно-кишечного тракта: оптимизация диагностики и трагетной терапии. Молекулярная медицина. 2013; 5: 3-7.

13. Roosenboom B., van Lochem E. G., Meijer J. et al. Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis. Cells. 2020 Apr 6;9(4):891. doi: 10.3390/cells9040891.

14. Ahluwalia B., Moraes L., Magnusson M. K., Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018 Apr;53(4):379-389. doi: 10.1080/00365521.2018.1447597.

15. Castro-Dopico T., Colombel J. F., Mehandru S. Targeting B cells for inflammatory bowel disease treatment: back to the future. Curr Opin Pharmacol. 2020 Dec;55:90-98. doi: 10.1016/j.coph.2020.10.002.

16. Wang, X., Hao, Gl., Wang, By. et al. Function and dysfunction of plasma cells in intestine. Cell Biosci. 2019 Mar 13;9:26. doi: 10.1186/s13578-019-0288-9.

17. Junhui Z., Guixiu S. Lymphocyte infiltration and key differentially expressed genes in the ulcerative colitis. Medicine (Baltimore). 2020 Aug 28;99(35): e21997. doi: 10.1097/MD.0000000000021997.

18. Sun X., Huang Y., Zhang Y. L., Qiao D., Dai Y. C. Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells. World J Gastroenterol. 2020 Dec 28;26(48):7593-7602. doi: 10.3748/wjg.v26.i48.7593.

19. Pararasa C., Zhang N., Tull T. J. et al. Reduced CD27-IgD- B Cells in Blood and Raised CD27-IgD- B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel Disease. Front Immunol. 2019 Mar 5;10:361. doi: 10.3389/fimmu.2019.00361.

20. Letizia M., Kaufmann U., Wang Y-H. et al. Store-Operated Calcium Entry Controls Innate and Adaptive Immune Cell Function in Inflammatory Bowel Disease. EMBO Mol Med. 2022 Sep 7;14(9): e15687. doi: 10.15252/emmm.202215687.

21. Rabe H., Malmquist M., Barkman C. et al. Distinct patterns of naive, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn’s disease. Clin Exp Immunol. 2019 Jul;197(1):111-129. doi: 10.1111/cei.13294.

22. Preisker S, Brethack A. K., Bokemeyer A. et al. Crohn’s Disease Patients in Remission Display an Enhanced Intestinal IgM+ B Cell Count in Concert with a Strong Activation of the Intestinal Complement System. Cells. 2019 Jan 21;8(1):78. doi: 10.3390/cells8010078.

23. Fu Y., Wang Z., Yu B. et al.Intestinal CD11b+ B Cells Ameliorate Colitis by Secreting Immunoglobulin A. Front Immunol. 2021 Nov 3;12:697725. doi: 10.3389/fimmu.2021.697725.

24. Degasperi G. R. Mucosal Immunology in the Inflammatory Bowel Diseases, Biological Therapy for Inflammatory Bowel Disease.IntechOpen. 2020. doi: 10.5772/intechopen.90037.

25. Kumric M., Zivkovic P. M., Kurir T. T. et al. Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease. Diagnostics (Basel). 2021 Dec 27;12(1):45. doi: 10.3390/diagnostics12010045.

26. Breedveld A., van Egmond M. IgA and FcαRI: Pathological Roles and Therapeutic Opportunities. Front Immunol. 2019 Mar 22;10:553. doi: 10.3389/fimmu.2019.00553.

27. Wei H., Wang J-Y. Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis.Int J Mol Sci. 2021 Feb 25;22(5):2284. doi: 10.3390/ijms22052284.

28. Hansen, I.S., Baeten, D.L.P., den Dunnen, J. The inflammatory function of human Ig A. Cell Mol Life Sci. 2019 Mar;76(6):1041-1055. doi: 10.1007/s00018-018-2976-8.

29. Fransen F., Zagato E., Mazzini E., et al. BALB/c and C57BL/6 mice differ in polyreactive IgA abundance, which impacts the generation of antigen-specific IgA and microbiota diversity. Immunity. 2015 Sep 15;43(3):527-40. doi: 10.1016/j.immuni.2015.08.011.

30. López-García L., Castro-Manrreza M.E. TNF-α and IFN-γ Participate in Improving the Immunoregulatory Capacity of Mesenchymal Stem/Stromal Cells: Importance of Cell-Cell Contact and Extracellular Vesicles.Int J Mol Sci. 2021 Sep 2;22(17):9531. doi: 10.3390/ijms22179531.

31. Baumgart D. C. Crohn’s disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. Second Edition. Berlin, Germany: Springer, 2017. doi: 10.1007/978-3-319-33703-6.

32. Komban, R.J., Strömberg, A., Biram, A. et al. Activated Peyerös patch B cells sample antigen directly from M cells in the subepithelial dome. Nat Commun. 2019 Jun 3;10(1):2423. doi: 10.1038/s41467-019-10144-w.

33. Keppler S. J., Goess M. C. Heinze J. M. The Wanderings of Gut-Derived IgA Plasma Cells: Impact on Systemic Immune Responses. Front Immunol. 2021 Apr 15;12:670290. doi: 10.3389/fimmu.2021.670290.

34. Cupi M. L., Sarra M., Marafini I. et al. Plasma Cells in the Mucosa of Patients with Inflammatory Bowel Disease Produce Granzyme B and Possess Cytotoxic Activities. J Immunol. 2014 Jun 15;192(12):6083-91. doi: 10.4049/jimmunol.1302238.

35. Karlsen T. H., Folseraas T., Thorburn D., Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017 Dec;67(6):1298-1323. doi: 10.1016/j.jhep.2017.07.022.

36. Manganis C. D., Chapman R. W., Culver E. L. Review of primary sclerosing cholangitis with increased IgG4 levels. World J Gastroenterol. 2020 Jun 21;26(23):3126-3144. doi: 10.3748/wjg.v26.i23.3126.

37. Seril D. N., Shen B. Diagnosis and Management of IgG4-associated Pouchitis. Practical Gastroenterology. 2014;(9):67-79.

38. Olpin J. D., Sjoberg B. P., Stilwill S. E. et al. Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease. Radiographics. 2017 Jul-Aug;37(4):1135-1160. doi: 10.1148/rg.2017160121.

39. Arato A., Savilahti E. IgG3 and IgG4 cells are increased in active ulcerative colitis. Digestion. 1990;47(1):35-41. doi: 10.1159/000200474.

40. Zinöcker M. K., Lindseth I. A. The Western Diet-Microbiome-Host Interaction and Its Role in Metabolic Disease. Nutrients. 2018 Mar 17;10(3):365. doi: 10.3390/nu10030365.

41. Singh S., Dulai P. S., Zarrinpar A. et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):110-121. doi: 10.1038/nrgastro.2016.181.

42. Park S., Kang Y., Koh H., Kim S. Increasing incidence of inflammatory bowel disease in children and adolescents: significance of environmental factors. Clin Exp Pediatr. 2020 Sep;63(9):337-344. doi: 10.3345/cep.2019.00500.

43. Jodeleit H., Milchram L., Soldo R. et al. Autoantibodies as diagnostic markers and potential drivers of inflammation in ulcerative colitis. PLoS One. 2020 Feb 12;15(2): e0228615. doi: 10.1371/journal.pone.0228615.

44. Stepanov Y., Tarasova T., Stoikevych M. et al. The study of tissue IgG4 in the mucous membrane of the colon in patients with inflammatory bowel disease. Gastroenterology. 2021; 55(4): 246-251. doi: 10.22141/2308-2097.55.4.2021.247916.

45. Song D. J., Jun S., Min Hu C. et al. Association of Serum Immunoglobulins Levels With Specific Disease Phenotypes of Crohn’s Disease: A Multicenter Analysis in China. Front Med (Lausanne). 2021 Apr 28;8:621337. doi: 10.3389/fmed.2021.621337.

46. Markmann C., Bhoj V. G. On the road to eliminating long-lived plasma cells-”are we there yet?”. Immunol Rev. 2021 Sep;303(1):154-167. doi: 10.1111/imr.13015.

47. Restellini S., Afif W. Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. J Clin Med. 2021 Mar 17;10(6):1242. doi: 10.3390/jcm10061242.

48. Abrahama B., Glassner K. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Curr Opin Gastroenterol. 2021 Jul 1;37(4):344-350. doi: 10.1097/MOG.0000000000000738.

49. Sandborn W. J., Rebuck R., Wang Y. et al. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 Mar;20(3):578-590.e4. doi: 10.1016/j.cgh.2021.02.025.

50. Bamias G., Cominelli F. Exploring the Early Phase of Crohn’s Disease. Clin Gastroenterol Hepatol. 2021 Dec;19(12):2469-2480. doi: 10.1016/j.cgh.2020.09.023.